大B细胞淋巴瘤的精准病理诊断  

Precision diagnosis of large B-cell lymphoma

作　　者：时云飞[1] 李向红[1] Shi Yunfei;Li Xianghong(Department of Pathology,Key Laboratory of Carcinogenesis and Translational Research/Ministry of Education,Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所病理科/恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《临床与实验病理学杂志》2025年第2期149-156,共8页Chinese Journal of Clinical and Experimental Pathology

摘　　要：大B细胞淋巴瘤(large B-cell lymphoma,LBCL)既往又被称为弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL),是最常见的淋巴瘤家族,侵袭性高,异质性强。WHO淋巴瘤分类不断细化并更新了LBCL的具体类型,力求更加准确地反映不同具体类型LBCL的生物学行为差异,并逐渐成为临床进行准确预后分层和制定治疗方案的重要依据。LBCL分型日趋精准必然要求病理医师的诊断更加精准化,同时淋巴瘤治疗药物不断推陈出新和治疗方式日趋多样化,也对LBCL的精准分型和靶向检测提出了更高的要求。基于此,笔者将结合自身工作经验和体会,对LBCL精准病理诊断相关内容进行系统的总结和梳理,以期帮助读者认识到LBCL精准诊断的重要性、全面准确地掌握相关概念和建立更加清晰的诊断思路。Large B-cell lymphoma(LBCL),formerly known as diffuse large B-cell lymphoma(DLBCL),is the most common type of lymphoma,characterized by high invasiveness and strong heterogeneity.The World Health Organization(WHO)lymphoma classification has been continually updated to better differentiate the biological behaviors of various subtypes of DLBCL.These updated classifications are increasingly important for prognosis stratification and treatment decisions for oncologists.The increasingly refined classification of DLBCL will inevitably require pathologists to make more precise diagnoses.Furthermore,the advances and growing diversity in lymphoma treatment also create a demand for precision diagnosis in LBCL,including therapy-target evaluation.Based on our own experience,we have systematically reviewed and summarized the current knowledge and progress in precision diagnosis of LBCL.This review aims to emphasize the importance of precision diagnosis in LBCL,help readers understand the relevant concepts more comprehensively and accurately,and promote the adoption of more reasonable diagnostic procedures.

关 键 词：弥漫大B细胞淋巴瘤 病理诊断 分子病理 免疫组织化学 

分 类 号：R733.4[医药卫生—肿瘤]